GW Pharmaceuticals Receives Approval for 5 New Patents for Epidiolex

GW Pharmaceuticals (Nasdaq:GWPH) recently announced that their company has received “Notices of Allowance” from the United States Patent and Trademark office for five new Epidiolex® patent applications for the company’s proprietary Cannabidiol (CBD) based pharmaceutical.

Epidiolex® is concentrated on treating rare, treatement resistant epilepsy conditions such as Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS). GW Pharmaceuticals has submitted regulatory applications for Epidiolex® in both the United States and Europe.

By granting Epidiolex® the Orphan Drug Designation the FDA has already labeled it as a safe and an effective treatment for a rare disease or disorder. The FDA has set a PDUFA goal date of June 27, 2018.


List of the New Patents

US 15/449,084           
A method of reducing seizure frequency in a patient suffering from a treatment-resistant childhood-onset epilepsy selected from Lennox-Gastaut syndrome or Dravet syndrome and who was previously treated with clobazam, comprising administering CBD and clobazam to the patient in need thereof, wherein the dose of clobazam used in combination with the CBD is reduced relative to the dose of clobazam administered to the patient prior to treatment with the CBD, wherein the CBD has a purity of at least 98 percent (w/w) CBD and comprises not more than 0.15 percent (w/w) THC.

US 15/449,124
A method of reducing seizure frequency in a patient with a treatment-resistant epilepsy, which is Lennox-Gastaut syndrome, comprising administering to the patient in need thereof clobazam and CBD, wherein the purity of the CBD is at least 98 percent (w/w) CBD and comprises not more than 0.15 percent (w/w) THC, wherein the dose of the CBD is at least 10 mg/kg/day.

US 15/449,185
A method of reducing seizure frequency in a patient with a treatment-resistant epilepsy, which is Dravet syndrome, comprising administering to the patient in need thereof clobazam and CBD, wherein the purity of the CBD is at least 98 percent (w/w) CBD and comprises not more than 0.15 percent (w/w) THC, wherein the dose of the CBD is at least 10 mg/kg/day.

US 15/449,204
A method of reducing convulsive seizure frequency in a patient with a treatment-resistant epilepsy, which is Lennox-Gastaut syndrome, comprising administering to the patient in need thereof CBD, wherein the CBD has a purity of at least 98 percent (w/w) CBD and comprises not more than 0.15 percent (w/w) THC, wherein the dose of the CBD is at least 10 mg/kg/day.

US 15/449,177
A method of reducing convulsive seizure frequency in a patient with a treatment-resistant epilepsy, which is Dravet syndrome, comprising administering to the patient in need thereof CBD, wherein the CBD has a purity of at least 98 percent (w/w) CBD and comprises not more than 0.15 percent (w/w) THC, wherein the dose of the CBD is at least 10 mg/kg/day.


Link to the Press Release

Related posts

Lifestyle Delivery Systems Inc. announces CSPA Group Inc. and LDS Scientific’s CannaStrips™ and Rèveur debut

creativemind

Medical Marijuana, Inc. Subsidiary HempMeds® Signs Agreement with National Distributor Mr. Checkout

creativemind

MedReleaf (TSE: LEAF) Announces 3rd Quarter Financials

Editor

Leave a Comment

%d bloggers like this: